Brokers Set Expectations for BDRX FY2028 Earnings

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Research analysts at Zacks Research issued their FY2028 EPS estimates for shares of Biodexa Pharmaceuticals in a research report issued on Monday, June 29th. Zacks Research analyst D. Bautz expects that the company will post earnings per share of $0.00 for the year.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. Weiss Ratings raised Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX stock opened at $2.85 on Tuesday. Biodexa Pharmaceuticals has a one year low of $2.45 and a one year high of $66.50. The company has a fifty day moving average of $3.37 and a 200-day moving average of $6.97.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings data on Friday, March 27th. The company reported $3.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.53.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.